Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eric Lynam

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology

Medicine

Hematology

2013

English

Anthracycline Efficacy in Vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types

Drug Delivery

Medicine

Pharmaceutical Science

1997

English

Related publications

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology

Hematology

2018

English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma

Hematological Oncology

English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology

English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology

Hematology

2019

English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology

Oncology

2019

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International

English

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Clinical Lymphoma, Myeloma and Leukemia

English

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eric Lynam

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Anthracycline Efficacy in Vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types

Related publications

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma